Friday 6th November 2026

13:45  Welcome and introduction (U. Novak, Bern)

Immunotherapies for lymphomas: basics (M. Wehrli, Bern)

13:50  Bispecifics: mode of action & problems (A. Stathis, Bellinzona)

14:20  CAR T-cells: mode of action & problems (C. Arber, Lausanne) 

Financial aspects (B. Kasenda, Basel)

14:50  Pricing & burden, and perspectives (K.N. Vokinger, Zürich)

15:30  Case presentation by attendees/discussion     

15:45  Coffee break

Indolent lymphomas (U. Mey, Chur)

16:15  CLL: new developments in the first line (O. Al-Sawaf, Köln)

16:45  FL: is R mono still an option & treatment goals (C. Renner, Zürich)

17:15  MCL: first and later lanes ( M. Dreyling, München)

17:45  Case presentation by attendees/discussion

18:30   Adjourn

Saturday 7th November 2026

Aggressive lymphomas: young & elderly (U. Novak, Bern)

08:00   First-line therapy: beyond R-CHOP & eligibility (A. Davies, Southampton)

08:30  Options for the relapsed setting: referral?! (T. Zenz, Zürich)

09:00  Sequencing the options: do we have the data? (F. Stenner, Basel)

09:30  Case presentation by attendees/discussion        

10:00  Coffee break

Controversials & ready for prime time? (N. Lang, Genève)

10:30  After care for CAR patients: looking for what? (C. Hirzel, Bern)

11:00  Choosing the therapy for the elderly patient (W. Rösler, Zürich)

11:30  Monitoring with circulating tumor DNA: ready? (D. Rossi, Bellinzona)

12:00  Wrap up and prize (U. Novak, Bern)        

12:15   End